Jennifer Brown, MD, PhD, Discusses Genomic Evolution of Pirtobrutinib Resistance

By Leah Sherwood, Jennifer R. Brown, MD, PhD - Last Updated: February 8, 2024

Dr. Brown discussed her abstract on the genomic evolution of pirtobrutinib resistance at the 2023 European Hematology Association Congress in Frankfurt, Germany.

Post Tags:EHA2023

Expert Panel Discusses Clinical Data, Practice of BTK Inhibitor, B-Cell Lymphoma 2 Inhibitor Use in CLL

Andrew MorenoChronic Lymphocytic Leukemia | March 7, 2025

The several considerations involved with these agent classes make discussions with patients of treatment decisions crucial.

Stepping Forward in CLL: Novel Agents and BTKi/BCL2i Combination Strategies

Melissa BadamoChronic Lymphocytic Leukemia | March 6, 2025

BTKi/BCL2i combinations may change how CLL treatment is offered over a patient’s lifespan, said Kerry Rogers, MD.

CD5-Targeting CAR T-Cell Therapy Receives FDA Orphan Drug Designation for T-Cell Lymphoma Use

Andrew MorenoT-Cell Lymphoma | January 30, 2025

Therapy also in development for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.

FDA Approves In-Vitro Assay to Identify B-Cell Lymphomas, Plasma Cell Neoplasms

Andrew MorenoAggressive B-Cell Lymphoma | January 29, 2025

The single-slide test helps clinicians differentiate more than 60 subtypes of these diseases from normal immune response.

Comparing Risk Scores for Disease Progression in Untreated CLL

Melissa BadamoChronic Lymphocytic Leukemia | January 29, 2025

The IPS-E, CR0, AIPS-E, CLL-IPI, and Barcelona-Brno risk scores can predict time to first treatment in CLL patients.

Jennifer Brown, MD, PhD, Discusses Genomic Evolution of Pirtobrutinib Resistance

Related Posts